Calmare Therapeutics (CTTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2010 | 01-2010 | 10-2009 | 07-2009 | 04-2009 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | N/A | 1,081 | 545 | 752 | 374 |
| Receivables | N/A | 143 | 303 | 200 | 371 |
| Inventories | N/A | 434 | N/A | N/A | N/A |
| TOTAL | $N/A | $1,768 | $970 | $1,159 | $886 |
| Non-Current Assets | |||||
| PPE Net | N/A | 176 | 211 | 203 | 218 |
| Other Non-Current Assets | 0 | 137 | 260 | 40 | 215 |
| TOTAL | $N/A | $313 | $471 | $243 | $432 |
| Total Assets | $N/A | $2,081 | $1,441 | $1,402 | $1,319 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 0 | 617 | 300 | 353 | 517 |
| Accrued Expenses | N/A | 500 | 761 | 682 | 446 |
| TOTAL | $N/A | $1,117 | $1,062 | $1,035 | $963 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $75 | $95 | $81 | $81 |
| Total Liabilities | $N/A | $1,192 | $1,156 | $1,116 | $1,044 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | N/A | 11,024 | 10,530 | N/A | 9,537 |
| Common Shares | N/A | 109 | 102 | 98 | 92 |
| Retained earnings | N/A | -39,263 | -38,517 | -37,762 | -36,939 |
| TOTAL | $N/A | $889 | $285 | $285 | $274 |
| Total Liabilities And Equity | $0 | $2,081 | $1,441 | $1,402 | $1,319 |